Figure 5. ASCs-derived extracellular vesicles exert a senoprotective effect on IL1β-induced senescence in chondrocytes. (A) Workflow of IL1β-induced senescence in primary human chondrocytes and treatment with different doses of ASCs-derived EVs: Low dose (LD), medium dose (MD) and high dose (HD). (B) Representative pictures of SA-β-Gal staining in chondrocytes (left panel; bars: 100 µm) and percentage of SA-β-Gal positive cells (n = 6, 7) (right panel). (C) Relative expression of Cyclin-Dependent Kinase Inhibitors in IL1β-treated chondrocytes (n = 6, 7). (D) Protein secretion in supernatants of IL1β-treated chondrocytes quantified by ELISA (n = 6). Data are shown as mean ± SEM. Statistical analysis used the Mann-Whitney test (B, C) or the Wilcoxon signed rank test (C) or the Wilcoxon matched pair signed rank test (D) for pair-wised comparisons versus the IL1β group. *p < 0.05, **p < 0.01.